特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
表紙
市場調査レポート
商品コード
666023

肝癌治療薬市場:市場規模、シェア、動向分析 - 治療薬クラス(標的療法、免疫療法)、主要国(米国、日本、英国、ドイツ、スペイン、イタリア、フランス)別 2016年~2022年

Liver Cancer Drugs Market Size, Share & Trends Analysis Report By Therapeutic Class (Targeted Therapy, Immunotherapy), By Country (U.S., Japan, U.K., Germany, Spain, Italy, France), And Segment Forecasts, 2016 - 2022

出版日: | 発行: Grand View Research, Inc. | ページ情報: 英文 92 Pages | 納期: 2-3営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=105.15円
肝癌治療薬市場:市場規模、シェア、動向分析 - 治療薬クラス(標的療法、免疫療法)、主要国(米国、日本、英国、ドイツ、スペイン、イタリア、フランス)別 2016年~2022年
出版日: 2018年06月14日
発行: Grand View Research, Inc.
ページ情報: 英文 92 Pages
納期: 2-3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の肝癌治療薬市場は、2016年から2022年にかけて19.4%のCAGRで推移し、2022年までに14億4,000万米ドル規模の市場に成長することが予測されています。新薬の入手性、強力なパイプラインの存在、治療薬の認知度の向上などが当市場の主な成長要因となっています。

当レポートでは、肝癌治療薬市場を調査し、疾患の概要、疫学、市場規模の推移と予測、市場動向、成長要因・阻害要因の分析、競合情勢、主要企業のプロファイルなど、包括的な情報を提供しています。

目次

第1章 調査方法

  • 情報調達
  • データ分析

第2章 エグゼクティブサマリー

第3章 疾患のプライマーと疫学

  • 病気のプライマー
  • 疫学

第4章 世界の肝癌治療薬市場の概要

  • 治療薬クラス
  • 市場規模と予測
  • 市場シェアの分布:企業別
  • 市場動向とブランド戦略
  • 特許満了の分析
  • 肝癌市場:成長要因と阻害要因
  • M&A、取引の情勢
  • 新興市場
  • 償還シナリオ
  • SWOT分析

第5章 肝癌治療薬のパイプライン

  • パイプライン概要
  • パイプライン予測

第6章 企業プロファイル

  • Bayer
  • Bristol-Myers Squibb
  • エーザイ
  • Exelixis
  • Merck

第7章 市場の見通し

  • 将来展望
  • 勝者と敗者
  • 新興企業と技術のプラットフォーム
  • 前途
図表

List of Tables

  • TABLE 1 Marketed Drugs for Liver Cancer
  • TABLE 2 Sales Performance by Therapeutic Class, 2016 - 22
  • TABLE 3 Sales Performance by Geographic Market, in $ million, 2016 - 22
  • TABLE 4 U.S. Patents for Current Liver Cancer Drugs
  • TABLE 5 R&D Pipeline Overview
  • TABLE 6 Gene Therapy Pipeline
  • TABLE 7 Late Stage Pipeline
  • TABLE 8 Lenvima
  • TABLE 9 Cabometyx
  • TABLE 10 Keytruda
  • TABLE 11 Cyramza
  • TABLE 12 Pexa - Vec (JX - 594)
  • TABLE 13 Pipeline Forecast of Leading Drugs
  • TABLE 14 Bayer Sales Forecast, 2016 - 2022
  • TABLE 15 Bayer Pipeline
  • TABLE 16 Bristol - Myers Squibb Sales Forecast, 2016 - 2022
  • TABLE 17 Bristol - Myers Squibb Pipeline
  • TABLE 18 Eisai Sales Forecast, 2016 - 2022
  • TABLE 19 Exelixis Sales Forecast, 2016 - 2022
  • TABLE 20 Exelixis Pipeline
  • TABLE 21 Merck Sales Forecast, 2016 - 2022

List of Figures

  • FIG. 1 Market research process
  • FIG. 2 Information Procurement
  • FIG. 3 Primary research pattern
  • FIG. 4 Market research approaches
  • FIG. 5 Value chain based sizing & forecasting
  • FIG. 6 QFD modelling for market share assessment
  • FIG. 7 Incidence and Mortality Rate of Liver Cancer per 100,000 in the U.S. (2000 - 12)
  • FIG. 8 Incidence and Mortality Rate of Liver Cancer per 100,000 in Japan (2000 - 12)
  • FIG. 9 Incidence and Mortality Rate of Liver Cancer per 100,000 in the U.K. (2000 - 12)
  • FIG. 10 Incidence and Mortality Rate of Liver Cancer per 100,000 in Spain (2000 - 12)
  • FIG. 11 Incidence and Mortality Rate of Liver Cancer per 100,000 in France (2000 - 12)
  • FIG. 12 Incidence and Mortality Rate of Liver Cancer per 100,000 in Italy (2000 - 12)
  • FIG. 13 Incidence and Mortality Rate of Liver Cancer per 100,000 in Germany (2000 - 12)
  • FIG. 14 Liver Cancer Market Share, by Therapeutic Class, 2016 - 22
  • FIG. 15 Regional Market Size, 2016 - 2022
  • FIG. 16 U.S. Liver Cancer Drugs Market, $ million (2016 - 22)
  • FIG. 17 Japan Liver Cancer Drugs Market, $ million (2016 - 22)
  • FIG. 18 Germany Liver Cancer Drugs Market, $ million (2016 - 22)
  • FIG. 19 France Liver Cancer Drugs Market, $ million (2016 - 22)
  • FIG. 20 U.K. Liver Cancer Drugs Market, $ million (2016 - 22)
  • FIG. 21 Italy Liver Cancer Drugs Market, $ million (2016 - 22)
  • FIG. 22 Spain Liver Cancer Drugs Market, $ million (2016 - 22)
  • FIG. 23 Liver Cancer Market Share, by Company, 2016 - 22
  • FIG. 24 Incidence and Mortality Rate of Liver Cancer per 100,000 in China (2000 - 12)
  • FIG. 25 Liver Cancer Market SWOT
  • FIG. 26 Bayer HCC Sales Forecast
  • FIG. 27 Bayer SWOT Analysis
  • FIG. 28 Bristol - Myers Squibb HCC Sales Forecast
  • FIG. 29 Bristol - Myers Squibb SWOT Analysis
  • FIG. 30 Eisai HCC Sales Forecast
  • FIG. 31 Eisai SWOT Analysis
  • FIG. 32 Exelixis HCC Sales Forecast
  • FIG. 33 Exelixis SWOT Analysis
  • FIG. 34 Merck HCC Sales Forecast
  • FIG. 35 Merck SWOT Analysis
目次
Product Code: GVR-2-68038-513-7

The global liver cancer drugs market size is expected to be valued at USD 1.47 billion by 2022, as per a new report by Grand View Research, Inc., expanding at a CAGR of 19.4% during the forecast period. The growth of liver cancer market is largely driven by factors such as availability of novel drugs, presence of strong pipeline, and rising public awareness. Widening base of liver cancer patients can be attributed to unhealthy lifestyles and growing geriatric population. This, in turn, is working in favor of the liver cancer therapeutics market. Therapeutic development in second-line setting for Nexavar-intolerant patients is estimated to have a major impact in the HCC space.

Liver cancer is the fifth most prevalent cancer worldwide and accounts for 9.0% of all cancer deaths. In 2012, 782,451 new cases of liver cancer were diagnosed, and 745,533 deaths were reported due to liver cancer. Primary liver cancer remains an important public health issue due to its extremely aggressive nature and poor survival rate. Hepatocellular carcinomas (HCCs) represents the majority (75-90%) of primary liver cancers. A noteworthy number of etiological factors of liver cancer, including hepatitis infection and cirrhosis, can be modified and present a strong prospect to reduce its incidence and mortality by preventive strategies such as lifestyle modification and hepatitis immunization.

Further key findings from the report suggest:

  • The U.S. accounted for more than 45.0% of the market in 2016. Multiple product launches, increasing adoption of novel therapeutics, and presence of a large target population are contributing to the growth of the market in the region
  • Approval of multiple novel drugs in recent years is one of the key factors augmenting the liver cancer treatment market. New immuno-oncology products and combination therapies are anticipated to change the landscape over the next years.
  • Combination regimens, specifically those including checkpoint inhibitors, will be introduced in the first-line setting to target major unmet needs, including overcoming tumour resistance, improving progression free survival, and maintaining quality of life
  • The liver cancer market pipeline is highly innovative and diverse. The market offers tremendous opportunities to develop breakthrough first-in-class therapies due to high unmet needs. In recent years, innovative treatment approaches such as oncolytic viruses or RNA interference (RNAi) technology have gained significant traction in the market

Some of the key players operating in this market are: Bayer, Bristol-Myers Squibb, Eisai, and Exelixis. Collaborations for development, broader product portfolios, and regional expansion in emerging markets are the key strategic undertakings of these companies to increase their market share.

Table of Contents

Chapter 1 Research Methodology

  • 1.1. Information procurement
  • 1.2. Information or Data Analysis
    • 1.2.1 Market Formulation & Validation

Chapter 2 Executive Summary

Chapter 3 Disease Primer and Epidemiology

  • 3.1. Disease Primer
  • 3.2. Epidemiology

Chapter 4 Global Liver Cancer Drugs Market Overview

  • 4.1 Market by Therapeutic Class
  • 4.2 Market Size and Forecast 2016 - 2022
  • 4.3 Market Share Distribution, by Company 2016 - 2022
  • 4.4 Market Dynamics and Brand Strategies
  • 4.5 Patent Expiry Analysis
  • 4.6 Liver Cancer Market: Drivers and Restraints
    • 4.6.1 Drivers
    • 4.6.2 Challenges
  • 4.7 M&A, Deal Landscape (2013 - 2017 YTD)
    • 4.7.1 Mergers & Acquisitions
    • 4.7.2 Deals Landscape
  • 4.8 Emerging Markets
  • 4.9 Reimbursement Scenario
  • 4.10 Liver Cancer Sector SWOT

Chapter 5 Liver Cancer Market: Pipeline Intelligence

  • 5.1. Pipeline Landscape
    • 5.1.1 Leading Drugs in Development
    • 5.1.2 Key R&D Trends
  • 5.2 Pipeline Landscape
    • 5.2.1 Late Stage Pipeline and Sales Forecast
    • 5.2.2 Profiles of Disruptive Drugs
  • 5.3 Global Pipeline Forecast

Chapter 6 Company Profiles

  • 6.1 Bayer
    • 6.1.1 Company Overview
    • 6.1.2 Current Product Portfolio
    • 6.1.3 Product Forecast Sales Through 2022
    • 6.1.4 Strategic Initiatives
      • 6.1.4.1 Key Company News Flow
    • 6.1.5 Pipeline Analysis & Overview
    • 6.1.6 SWOT
  • 6.2 Bristol-Myers Squibb
    • 6.2.1 Company Overview
    • 6.2.2 Current Product Portfolio
    • 6.2.3 Product Forecast Sales Through 2022
    • 6.2.4 Strategic Initiatives
      • 6.2.4.1 Key Company News Flow
    • 6.2.5 Pipeline Analysis & Overview
    • 6.2.6 SWOT
  • 6.3 Eisai
    • 6.3.1 Company Overview
    • 6.3.2 Current Product Portfolio
    • 6.3.3 Product Forecast Sales Through 2022
    • 6.3.4 Strategic Initiatives
      • 6.3.4.1 Key Company News Flow
    • 6.3.5 Pipeline Analysis & Overview
    • 6.3.6 SWOT
  • 6.4 Exelixis
    • 6.4.1 Company Overview
    • 6.4.2 Current Product Portfolio
    • 6.4.3 Product Forecast Sales Through 2022
    • 6.4.4 Strategic Initiatives
      • 6.4.4.1 Key Company News Flow
    • 6.4.5 Pipeline Analysis & Overview
    • 6.4.6 SWOT
  • 6.5 Merck
    • 6.5.1 Company Overview
    • 6.5.2 Current Product Portfolio
    • 6.5.3 Product Forecast Sales Through 2022
    • 6.5.4 Strategic Initiatives
      • 6.5.4.1 Key Company News Flow
    • 6.5.5 Pipeline Analysis & Overview
    • 6.5.6 SWOT

Chapter 7 Market Outlook

  • 7.1 What the Future Holds
  • 7.2 The Winners and Losers
    • 7.2.1 Winners
    • 7.2.2 Losers
  • 7.3 Emerging Companies & Technology Platforms
  • 7.4 The Road Ahead
株式会社グローバルインフォメーション
© Copyright 1996-2020, Global Information, Inc. All rights reserved.